Trade Repligen Corp - RGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.34 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 162.67 |
| Open | 163.28 |
| 1-Year Change | -5.33% |
| Day's Range | 159.85 - 163.28 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 16, 2025 | 162.67 | 8.72 | 5.66% | 153.95 | 164.18 | 153.67 |
| Jan 15, 2025 | 157.22 | -0.73 | -0.46% | 157.95 | 161.40 | 151.61 |
| Jan 14, 2025 | 156.50 | 1.71 | 1.10% | 154.79 | 159.64 | 150.61 |
| Jan 13, 2025 | 158.40 | 7.11 | 4.70% | 151.29 | 160.25 | 151.29 |
| Jan 10, 2025 | 154.66 | 3.14 | 2.07% | 151.52 | 154.93 | 149.64 |
| Jan 8, 2025 | 154.57 | 4.09 | 2.72% | 150.48 | 155.34 | 148.95 |
| Jan 7, 2025 | 153.41 | -0.59 | -0.38% | 154.00 | 158.24 | 152.34 |
| Jan 6, 2025 | 153.87 | 5.39 | 3.63% | 148.48 | 157.57 | 148.48 |
| Jan 3, 2025 | 149.76 | 6.74 | 4.71% | 143.02 | 151.90 | 141.30 |
| Jan 2, 2025 | 142.93 | -1.06 | -0.74% | 143.99 | 145.65 | 141.72 |
| Dec 31, 2024 | 143.79 | -0.38 | -0.26% | 144.17 | 145.32 | 142.59 |
| Dec 30, 2024 | 143.75 | 1.32 | 0.93% | 142.43 | 144.78 | 140.45 |
| Dec 27, 2024 | 145.49 | 2.54 | 1.78% | 142.95 | 146.23 | 142.95 |
| Dec 26, 2024 | 145.60 | 1.20 | 0.83% | 144.40 | 147.81 | 142.28 |
| Dec 24, 2024 | 146.37 | 2.92 | 2.04% | 143.45 | 147.32 | 141.23 |
| Dec 23, 2024 | 145.53 | 5.00 | 3.56% | 140.53 | 145.95 | 140.53 |
| Dec 20, 2024 | 144.46 | -0.76 | -0.52% | 145.22 | 150.60 | 143.46 |
| Dec 19, 2024 | 146.36 | 0.75 | 0.52% | 145.61 | 148.77 | 143.90 |
| Dec 18, 2024 | 147.04 | -9.00 | -5.77% | 156.04 | 158.93 | 146.39 |
| Dec 17, 2024 | 158.04 | -1.01 | -0.64% | 159.05 | 160.46 | 157.18 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Repligen Company profile
About Repligen Corporation
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Repligen Corporation revenues increased 83% to $670.5M. Net income increased from $59.9M to $128.3M. Revenues reflect Product revenue - Filtration products segment increase from $174.9M to $403.5M, Product revenue - Protein products segment increase of 53% to $123.7M, Europe segment increase of 83% to $254.8M, North America segment increase of 56% to $274.9M.
Equity composition
Common Stock $.01 Par, 01/11, 40M auth., 30,787,307 issd. Insiders & strategic holders own 13.21%. PO 5/91, 2M shares @ $12.50 by Lehman Bros. Public Offering 2/94, 2.9M shares @ $6 by Lehman Brothers.
| Industry: | Medical Equipment, Supplies & Distribution (NEC) |
Building 1, Suite 100
41 Seyon Street
WALTHAM
MASSACHUSETTS 02453
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com